MiMedx Group, Inc (NASDAQ:MDXG) Receives $8.50 Average Price Target from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $8.50.

A number of brokerages recently weighed in on MDXG. Craig Hallum lowered their price target on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citizens Jmp dropped their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th.

Institutional Trading of MiMedx Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC boosted its stake in shares of MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after purchasing an additional 1,725,458 shares during the last quarter. Nantahala Capital Management LLC bought a new stake in shares of MiMedx Group during the third quarter worth approximately $10,237,000. Marshall Wace LLP lifted its holdings in MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after buying an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. bought a new position in MiMedx Group in the fourth quarter valued at approximately $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its stake in MiMedx Group by 283.0% in the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after acquiring an additional 1,022,202 shares during the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Performance

MiMedx Group stock opened at $3.95 on Friday. The stock has a 50-day simple moving average of $3.65 and a 200 day simple moving average of $4.60. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.99. The stock has a market capitalization of $588.35 million, a price-to-earnings ratio of 19.75 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. On average, research analysts anticipate that MiMedx Group will post -0.09 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.